Samuel Bates Martin is CFO & VP at Celldex Therapeutics, Inc. (CLDX). They have made 7 open-market trades across 1 company since 2020, most recently 2026-01-02.
CIK 0001709024
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $30K since 2020, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CLDX | 32,942 | $907K |
Shares reported on the most recent Form 4, priced at the 2026-01-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLDX | SELL | 2024-06-14 | 2024-06-18 | $35.42 | $1.2M | +13.1% | +9.0% | +24.4% |
| CLDX | SELL | 2024-05-30 | 2024-06-03 | $34.05 | $1.2M | +10.8% | +9.2% | +26.2% |
| CLDX | SELL | 2022-08-11 | 2022-08-15 | $36.58 | $1.4M | -11.6% | -16.8% | -0.3% |
| CLDX | SELL | 2021-12-23 | 2021-12-28 | $42.00 | $399K | -9.8% | -31.8% | -15.9% |
| CLDX | SELL | 2021-11-15 | 2021-11-17 | $43.56 | $828K | -12.6% | -11.2% | -25.1% |
| CLDX | SELL | 2021-08-10 | 2021-08-12 | $45.25 | $124K | +7.2% | +18.1% | -0.2% |
| CLDX | BUY | 2020-06-09 | 2020-06-10 | $3.05 | $30K | +188.9% | +161.3% | +154.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.